Cardiff Oncology Inc. sell DrMabuse
Start price
06.09.20
/
50%
€4.94
Target price
19.09.20
-
Performance (%)
49.80%
End price
19.09.20
€7.40
Summary
This prediction ended on 19.09.20 with a price of €7.40. The price for Cardiff Oncology Inc. massively increased, which is bad news for the SELL prediction by DrMabuse. DrMabuse has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Cardiff Oncology Inc. | -5.274% | -5.274% | 87.099% | -59.741% |
iShares Core DAX® | -1.471% | 1.895% | 25.178% | 22.236% |
iShares Nasdaq 100 | -0.486% | 4.395% | 29.415% | 42.175% |
iShares Nikkei 225® | -2.115% | 2.450% | 20.561% | 6.454% |
iShares S&P 500 | 0.394% | 3.118% | 29.456% | 42.672% |
According to DrMabuse what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?
Pros
Cons
High risks for its business
Comments by DrMabuse for this prediction
In the thread Trovagene diskutieren
Sell Cardiff Oncology Inc.
In the thread Trading Trovagene
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by DrMabuse for Cardiff Oncology Inc.
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€7.40
19.09.20
19.09.20
-
29.09.20
29.09.20
72.97%
29.09.20
29.09.20
High risks for its business
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.34
03.09.20
03.09.20
-
03.09.20
03.09.20
-
03.09.20
03.09.20
High risks for its business
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€6.65
22.08.20
22.08.20
-
03.09.20
03.09.20
-11.28%
03.09.20
03.09.20
High risks for its business
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€5.40
08.08.20
08.08.20
-
21.08.20
21.08.20
23.15%
21.08.20
21.08.20
High risks for its business
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€3.80
25.07.20
25.07.20
-
08.08.20
08.08.20
42.11%
08.08.20
08.08.20
High risks for its business
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.06
14.06.20
14.06.20
-
27.06.20
27.06.20
111.65%
27.06.20
27.06.20
High risks for its business